BACKGROUNDThe Medtronic InSync Sentry is the first available cardiac resynchronization therapy defibrillator (CRT-D) which can monitor fluid status by measuring intrathoracic impedance. This study was designed to observe the effectiveness of intrathoracic impedance monitoring on detecting aggravation of heart failure.

METHODSWe retrospectively analyzed the clinical data of 14 consecutive patients. Patients were regularly followed up every 3 - 6 months after the implantation. At each visit, interrogation of the device was done. Patients were instructed to inform the researcher on hearing the device alert, and to take extra 40 milligrams of furosemidum if they had aggravated symptoms later. If the symptoms could not be relieved, they were asked to see a doctor. Data about heart failure hospitalization were collected from the medical record.

RESULTSDuring 18 - 48 months follow-up, a total of 7 patients encountered 28 alert events. On one hand, alert events appeared before all deteriorated symptoms and heart failure hospitalizations. On the other hand, there were 23 alerts followed by deterioration of heart failure symptoms, and 2 alerts related to 2 hospitalizations caused by pulmonary infection in one patient. Only 5 patients were hospitalized 10 times for deterioration of cardiac function.

CONCLUSIONThe function of intrathoracic impedance monitoring is reliable in predicting deterioration of heart failure.